news banner 2107 2

News

Print

HIV identified as leading risk factor for stroke in young African adults

on .

hivstroke

HIV infection is the leading risk factor for stroke in young African adults, a new study by the University of Liverpool’s Institute of Infection and Global Health has found.


The incidence of stroke is on the increase across most of sub-Saharan Africa. In countries like Malawi, a substantial proportion of stroke patients are young adults, and have a low prevalence of established risk factors such as high blood pressure, diabetes, obesity and smoking.


Now, in collaboration with the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, researchers have examined the role of HIV, its treatment, and its interaction with high blood pressure as risk factors for stroke in Malawian adults.

Print

MLW dedicated to strengthening leadership and management through training.

on .

leadershipgroup

The Malawi Liverpool Wellcome Trust has embarked on a program that is aimed at strengthening leadership and management at MLW through training.


According to MLW’s Chief Operations Officer Paul Clough, the trainings are being conducted to create greater capacity at management level within MLW as it expands so that there should be leaders who can assume greater responsibility for its success.

 
He said “There are many factors in the success of MLW but undoubtedly one of the most significant ones is how well we manage and lead the organisation”.

Print

How antimalarial and antiretroviral drugs interact in HIV-malaria co-infected adults

on .

CliffopicClifford George Banda

In order to understand how effective and safe antimalarials are in treating malaria when given to adults who are HIV-positive and are taking antiretroviral therapy (ART) the Malawi-Liverpool-Wellcome Trust Clinical Research Programme is implementing the ADAPT II study in Blantyre and Chikwawa.


Artemisinin-based combination therapies (ACTs) are the current first-line antimalarials. It is known that certain ARTs can alter the level of the artemisinins’ partner drugs in ACTs when taken together. This has been a cause for concern since increased levels of these partner drugs can lead to toxicity for instance of the heart (i.e. cardiotoxicity).